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Critical care physicians have debated an appropriate
term for the clinical phase preceding acute kidney
injury (AKI). The recent development of cell cycle
arrest biomarkers that signal the potential
development of AKI is part of an evolution in the
molecular diagnosis and understanding of AKI. It is
proposed that the pre-injury phase that leads to AKI
can be described as “acute kidney stress”. This term
has the potential to expand horizons in regard to the
early detection of situations that will lead to AKI and
the early implementation of corrective measures.is part of an evolution in the molecular diagnosis andCritical care physicians have debated an appropriate
term for the clinical phase preceding acute kidney injury
(AKI). “Renal angina” has been proposed [1]; however, it
is recognized that AKI can result from non-ischemic
mechanisms, and AKI is not associated with pain. A var-
iety of etiologies for AKI have been identified, including
sepsis, inflammation, toxins, and heart failure. Examples
of complex mechanisms include the cardio-renal syn-
dromes, which are related to interactions between the
kidney and the cardiovascular system [2]. The complex-
ity of defining AKI or a “kidney attack” using standard
measures of kidney function has been recognized by
nephrologists from centers around the world [3]. An-
other term that has been discussed is “subclinical” acute
kidney injury [4].
Early diagnosis of AKI has challenged intensivists and
critical care nephrologists. The delay in elevation of
creatinine to approximately 24–48 h after AKI makes* Correspondence: nevinkatz@aol.com
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early diagnosis of AKI. Although the renal biomarker
neutrophil gelatinase-associated lipocalin (NGAL) can
be a valuable clinical test to alert clinicians to subclinical
AKI, its lack of specificity has limited its use as a sole in-
dicator of AKI [5]. A variety of renal biomarkers have
now been identified and have the potential to enhance
the understanding and diagnosis of AKI, particularly as
biomarker monitoring is combined with monitoring
changes in renal function [6]. The use of biomarkers in
characterizing cardio-renal syndromes has been de-
scribed [7]. The recent identification of cell cycle arrest
biomarkers that signal the potential development of AKI
understanding of AKI [8]. These biomarkers are released
by kidney cells along a path which may lead to AKI dur-
ing a pre-injury phase.
It is proposed that the pre-injury phase that leads to
AKI can be described as “acute kidney stress” (AKS).
The term AKS seems appropriate as the understanding
of AKI evolves. It is debatable if AKS is a condition of
very early injury or a condition of increased susceptibil-
ity to exposures that lead to AKI. In fact the role of the
expressed biomarker molecules may represent a way to
monitor an initial damage, but also an attempt of the
kidney to proceed towards repair and avoid maladaptive
repair and progression towards fibrosis.
Working out criteria for AKS will assist critical care
teams in making clinical adjustments before AKI occurs.
Potential criteria for diagnosis of AKS include indices of
renal perfusion, such as urine output per minute,
changes in renal cell function, and detection of bio-
markers that reflect metabolic impairment, or kidney
“cell cycle arrest”. The criteria in part could be based on
parameters such as those used to define the first stages
of AKI in the Risk, Injury, Failure, Loss of kidney func-
tion and End-stage kidney disease (RIFLE), Acute Kidneyticle is distributed under the terms of the Creative Commons Attribution 4.0
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Global Outcome (KDIGO) criteria.
Recent developments to detect and monitor renal im-
pairment provide innovative criteria to define AKS. It is
well recognized that serum creatinine becomes elevated
late in the early stages of AKI. This raises the challenge of
measuring glomerular filtration rate in real time [9]. In-
novative technology is being developed which may pro-
vide such measurements in the intensive care unit (ICU).
To address the issue of the late elevation in serum creatin-
ine, the measure of “renal functional reserve” has been de-
scribed as a parameter of renal frailty [10]. Remarkably, in
adults, technology to monitor renal blood flow has yet to
be developed. Currently, urine flow is used as a surrogate
to monitor renal perfusion. Areas for development include
real time monitoring of renal cell perfusion. The ADQI
XIII Work Group has addressed the challenge of monitor-
ing for conditions creating renal ischemia [11].
AKI following major cardiac surgery remains an im-
portant source of patient morbidity and mortality.
With the increasing complexity of cardiac surgical
cases, this complication is being recognized with in-
creased frequency at major centers around the world
[12]. An important cause of cardiac surgery-associated
AKI is thought to be inadequate blood flow to the
kidney while the patient is on cardiopulmonary by-
pass and in the ICU due to suboptimal management
of hemodynamics. Over the years, development of
management protocols has been impeded by lack of
technology to directly measure blood flow to the
kidney. The use of cerebral oximetry to detect blood
pressure excursions below the cerebral autoregulation
threshold represents an innovative technology to alert
physicians to hemodynamics that may result in AKI
[13]. Such technology is now available for monitoring
patients in the operating room and the ICU.
Renal ischemia related to infusion of vasoconstrictors or
to local impairment of flow due to renal artery stenoses
may go undetected until AKI occurs. Monitoring renal cell
physiologic function for AKS could alert critical care pro-
fessionals to flawed goals of hemodynamic management.
Hemodynamic goals based on standard ICU guidelines, ra-
ther than physiologic monitoring, may lead to undetected
renal ischemia, as individual patients may have unique ar-
terial and/or venous pressure requirements.
Another issue in the diagnosis of AKS and its implica-
tions for long-term outcome is whether AKS may have
an impact on the future development of chronic kidney
disease (CKD), kidney frailty, or susceptibility to insults.
Multiple AKS events may produce progressive inflam-
mation, apoptosis, G2 cell cycle arrest, epithelial to
mesenchymal transition, fibrosis and CKD. This could
be a newly identified mechanism of nephroangiosclerosis
(which up till today has an unknown pathogenesis).It is anticipated that the term AKS could become in-
creasingly useful as clinicians develop methods to diagnose
and treat the early stages of AKI. This in turn should have
a major impact on patient outcomes and healthcare costs.
The expanded use of advanced technology, such as ven-
tricular assist devices and extracorporeal membrane oxy-
genation (ECMO), to support cardio-respiratory function
has led to the ICU being an extension of the operating
room [14]. Use of this innovative supportive technology
has been associated with increased risk of AKI [15, 16].
These developments highlight the need to define and
identify the pre-AKI phase, which could be termed AKS.
Combining innovative monitoring of renal function
with identification of new biomarkers of kidney stress
and injury could lead to the early diagnosis of AKS, and
the implementation of corrective hemodynamic and
pharmacologic management. An important issue when
renal impairment is occurring is timing the initiation of
renal replacement therapy. A score has been developed
to assist with this decision [17].
A focus on the metabolic mechanisms of AKS and the
associated impairments of renal cell function has the po-
tential to lead to innovative monitoring technology and
protocols. The result would be earlier changes in clinical
care to prevent kidney cell injury. The importance of in-
terventions to prevent or reduce the extent of AKI is
highlighted by the recognition that AKI is associated with
the development of CKD and its associated mortality [18].
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